Kunal Rai, Ph.D.
Department of Genomic Medicine
I joined the Wall Lab at Harvard Medical School on 2011 as a visiting scholar when I was pursuing my PhD in HUST, China. After finished my PhD, I started my postdoc research at Harvard and investigated cancer genomics research, with a focus on the clinical impact of whole-genomic data in personalized medicine and genomic pathology. At the Rai lab, I engaged in the cancer epigenomics research which focused on understanding the role of epigenome in cancer progression and epigenetic basis for immunotherapy responses. My research goal is to develop systematic approaches to discover and characterize genomic and epigenetic changes that program cancer development in order to derive a deeper understanding of the molecular networks that lead to malignant transformation and to drive the translation of these findingsinto clinically useful therapeutics.
Christopher Terranova, Ph.D.
My primary research interests involve understanding the epigenetic mechanisms responsible for controlling the spatial organization of chromatin structure during melanoma progression, including the improper availability of cis-elements, long-range chromosomal interactions, promoter/enhancer interactions and the misregulation of transcriptional machinery. Currently, we are working to define the epigenetic landscape of various melanoma subtypes using combinatorial chromatin patterns.
Elias Orouji, M.D., Ph.D.
I am a physician and genomic medicine cancer specialist, currently working as a postdoctoral fellow at the University of Texas MD Anderson Cancer Center. I am a graduate of Heidelberg University, Germany and a member of American Society of Clinical Oncology. My research interests include genomic/epigenomic regulations in different types of cancer, targeted therapies and application of precision medicine in the treatment of cancer.
Veena Kochat, Ph.D.
We are currently examining the various epigenomic factors that drive the transformation of neurofibroma to malignant peripheral nerve sheath tumor in Type I neurofibromatosis patients by high throughput sequencing studies. We are interested in exploring the non-canonical PRC2-independent role of EZH2 in activating oncogenic signaling pathways in MPNST. Our study aims to develop a combinational therapeutic approach involving epigenetic inhibitors and non-canonical EZH2-mediated signaling pathway inhibitors for MPNST patient cohorts.
Zhiyi Liu, Ph.D.
I focused on identifying the epigenetic drivers of the tumorigenesis of head and neck squamous cell carcinomas (HNSCCs). The genetic alterations of the TP53 gene (encoding p53 the "genome guardian") play the most important role in the malignant transformation of the head and neck squamous cells. A majority of HNSCC tumors (80%) has mutated TP53. Understanding the epigenetic regulations in the contexts of different types of TP53 mutations in HNSCC tumors will help us to identify novel therapeutic targets for anticancer treatment against HNSCCs.
I pursued my Masters degree in Molecular Biotechnology at the University of Houston, and joined MD Anderson cancer center as a Research Assistant II. I am currently studying the role of APOBEC1/PUS1 in colorectal cancer; also I am investigating the effects of various genetic and epigenetic inhibitors on different cancer cell lines. My future ambition is to go to graduate school to further enhance my knowledge in molecular therapeutics and strive to bring advancements in molecular therapeutics for the treatment of cancer.